🇺🇸 FDA
Patent

US 10900041

Antisense oligonucleotides for use in treating Alzheimer's disease

granted A61KA61K31/713

Quick answer

US patent 10900041 (Antisense oligonucleotides for use in treating Alzheimer's disease) held by ProQR Therapeutics II B.V. expires Mon Jan 21 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
ProQR Therapeutics II B.V.
Grant date
Tue Jan 26 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 21 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
14
CPC classes
A61K, A61K31/713